Publication:
Mitochondria-targeting selenophene-modified BODIPY-based photosensitizers for the treatment of hypoxic cancer cells

dc.contributor.coauthorKaraman, Osman
dc.contributor.coauthorGedik, M. Emre
dc.contributor.coauthorGünaydin, Gürcan
dc.contributor.coauthorGünbaş, Görkem
dc.contributor.departmentDepartment of Chemistry
dc.contributor.departmentDepartment of Chemistry
dc.contributor.kuauthorAlmammadov, Toghrul
dc.contributor.kuauthorKölemen, Safacan
dc.contributor.kuprofileResearcher
dc.contributor.kuprofileFaculty Member
dc.contributor.otherDepartment of Chemistry
dc.contributor.researchcenterKoç University Surface Science and Technology Center (KUYTAM) / Koç Üniversitesi Yüzey Teknolojileri Araştırmaları Merkezi (KUYTAM)
dc.contributor.schoolcollegeinstituteCollege of Sciences
dc.contributor.schoolcollegeinstituteCollege of Sciences
dc.contributor.yokidN/A
dc.contributor.yokid272051
dc.date.accessioned2024-11-09T23:04:57Z
dc.date.issued2019
dc.description.abstractTwo red-absorbing, water-soluble and mitochondria (MT)-targeting selenophene-substituted BODIPY-based photosensitizers (PSs) were realized (BOD-Se, BOD-Se-I), and their potential as photodynamic therapy (PDT) agents were evaluated. BOD-Se-I showed higher O-1(2) generation yield thanks to the enhanced heavy-atom effect, and this derivative was further tested in detail in cell culture studies under both normoxic and hypoxic conditions. BOD-Se-I not only effectively functioned under hypoxic conditions, but also showed highly selective photocytotoxicity towards cancer cells. The selectivity is believed to arise from differences in mitochondrial membrane potentials of healthy and cancerous cells. To the best of our knowledge, this marks the first example of a MT-targeted BODIPY PS that functions under hypoxic conditions. Remarkably, thanks to the design strategy, all these properties where realized by a compound that was synthesized in only five steps with 32% overall yield. Hence, this material holds great promise for the realization of next-generation PDT drugs for the treatment of hypoxic solid tumors.
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue22
dc.description.openaccessNO
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume14
dc.identifier.doi10.1002/cmdc.201900380
dc.identifier.eissn1860-7187
dc.identifier.issn1860-7179
dc.identifier.quartileQ2
dc.identifier.scopus2-s2.0-85074757094
dc.identifier.urihttp://dx.doi.org/10.1002/cmdc.201900380
dc.identifier.urihttps://hdl.handle.net/20.500.14288/8728
dc.identifier.wos494414400001
dc.keywordsPhotodynamic therapy
dc.keywordsBODIPY
dc.keywordsSinglet oxygen
dc.keywordsHypoxia
dc.keywordsMitochondria
dc.languageEnglish
dc.publisherWiley-V C H Verlag Gmbh
dc.sourceChemmedchem
dc.subjectChemistry, medicinal
dc.subjectPharmacology
dc.subjectPharmacy
dc.titleMitochondria-targeting selenophene-modified BODIPY-based photosensitizers for the treatment of hypoxic cancer cells
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.authorid0000-0002-1336-4650
local.contributor.authorid0000-0003-4162-5587
local.contributor.kuauthorAlmammadov, Toghrul
local.contributor.kuauthorKölemen, Safacan
relation.isOrgUnitOfPublication035d8150-86c9-4107-af16-a6f0a4d538eb
relation.isOrgUnitOfPublication.latestForDiscovery035d8150-86c9-4107-af16-a6f0a4d538eb

Files